AbbVie Inc.
NYSEABBV heads into its May 8 Q1 earnings with the analyst community firmly in the bull camp — and quietly raising the bar. The clearest signal ahead of the print is the strength of recent analyst upgrades. Morgan Stanley lifted its target to $278 from $270 last week, maintaining Overweight. Canaccord Genuity raised to $265 and Evercore ISI pushed to $236 on Monday. The consensus mean…
ABBV cost to borrow jumps to 0.48%, up 128% in one week as short interest climbs 7.9% over the same period.
Snapshot as of 7 May 2026
ABBV heads into its May 8 Q1 earnings with the analyst community firmly in the bull camp — and quietly raising the bar. The clearest signal ahead of the print is the strength of recent analyst upgrades. Morgan Stanley…
ABBV delivered what management called an "excellent start to 2026" on April 29, with immunology and neuroscience strength driving a beat that lifted shares 3.1% on the day. Yet even as the stock reclaimed $203.89 and…
AbbVie reports Wednesday with short positioning at a three-week low. The options market shows mild bearish tilt while analyst activity remains mixed. Short interest stands at 1.10% of float as of April 23. That's down…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABBV — free to start on ORTEX.
Sign up for free →Open ABBV on ORTEX